Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cholesterol drug inclisiran tested in everyday patients

NCT ID NCT05399992

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 847 adults with high cholesterol or mixed dyslipidemia who are starting inclisiran, a newer cholesterol-lowering drug. Researchers want to see how much LDL cholesterol drops after 10 months and how well patients stick with the treatment in real-world settings. The goal is to understand if inclisiran works effectively outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

inclisiran

What this could lead to

If successful, this study could show that inclisiran effectively lowers LDL cholesterol in routine care, helping doctors manage high cholesterol more conveniently.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It only looks at short-term adherence and cholesterol changes, not long-term health outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia, familial combined, LPL related

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIXED DYSLIPIDEMIA PRIMARY HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

  • Novartis Investigative Site

    Feldkirch, 6807, Austria

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Linz, 4021, Austria

  • Novartis Investigative Site

    Sankt Veit im Pongau, 5621, Austria

  • Novartis Investigative Site

    Vienna, 1090, Austria

  • Novartis Investigative Site

    Vienna, 1180, Austria

  • Novartis Investigative Site

    Shenzhen, Guangdong, 518000, China

  • Novartis Investigative Site

    Holon, Gush Dan, 5845997, Israel

  • Novartis Investigative Site

    Petah Tikva, 4941492, Israel

  • Novartis Investigative Site

    Tel Aviv, 6801296, Israel

  • Novartis Investigative Site

    Kuala Lumpur, Kuala Lumpur, 50470, Malaysia

  • Novartis Investigative Site

    Kuala Lumpur, 50400, Malaysia

  • Novartis Investigative Site

    Riyadh, Saudi, 11643, Saudi Arabia

  • Novartis Investigative Site

    Jeddah, 23311, Saudi Arabia

  • Novartis Investigative Site

    Tabuk, 47512, Saudi Arabia

  • Novartis Investigative Site

    Fribourg, CH, 1708, Switzerland

  • Novartis Investigative Site

    Basel, 4031, Switzerland

  • Novartis Investigative Site

    Geneva, 1211, Switzerland

  • Novartis Investigative Site

    Lausanne, 1011, Switzerland

  • Novartis Investigative Site

    Olten, 4600, Switzerland

  • Novartis Investigative Site

    Sankt Gallen, 9007, Switzerland

  • Novartis Investigative Site

    Zurich, 8032, Switzerland

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

  • Novartis Investigative Site

    Abu Dhabi, Abu Dhabi Emirate, 00000, United Arab Emirates

  • Novartis Investigative Site

    Dubai, United Arab Emirates, 7272, United Arab Emirates

  • Novartis Investigative Site

    Abu Dhabi, United Arab Emirates

  • Novartis Investigative Site

    Al Ain City, United Arab Emirates

  • Novartis Investigative Site

    Dubai, United Arab Emirates

  • Novartis Investigative Site

    High Wycombe, Buckinghamshire, HP11 2TR, United Kingdom

  • Novartis Investigative Site

    Louth, Lincolnshire, LN11 7QU, United Kingdom

  • Novartis Investigative Site

    Sunderland, Tyne and Wear, SR4 7TP, United Kingdom

  • Novartis Investigative Site

    Belfast, BT16 1RH, United Kingdom

  • Novartis Investigative Site

    Bromwich, B71 4HJ, United Kingdom

  • Novartis Investigative Site

    Burton-on-Trent, DE13 0RB, United Kingdom

  • Novartis Investigative Site

    Cardiff, CF14 4XW, United Kingdom

  • Novartis Investigative Site

    Hull, HU3 2RW, United Kingdom

  • Novartis Investigative Site

    Lancaster, LA1 4RP, United Kingdom

  • Novartis Investigative Site

    Liverpool, L7 8XP, United Kingdom

  • Novartis Investigative Site

    London, NW3 2QG, United Kingdom

  • Novartis Investigative Site

    Middlesex, UB9 6JH, United Kingdom